PLSM vs TXMD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
PLSM exhibits severe fundamental weakness as evidenced by a Piotroski F-Score of 2/9, placing it in the 'Weak' health category. While the company shows explosive top-line revenue growth of 578.30% and impressive gross margins of 84.16%, it is unable to translate this into profitability, with a profit margin of -39.61%. The technical trend is completely bearish (0/100) with a 50.4% decline over the past year. Despite a very strong liquidity position (Current Ratio 7.88), the lack of earnings and poor financial health scores make this a high-risk speculative asset.
TXMD exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows strong top-line revenue growth of 33.9% and maintains a healthy current ratio of 3.02, these are offset by a disastrous operating margin of -108.51% and a 5-year price collapse of -96.5%. The stock is currently trading near its book value (P/B 0.94), but the lack of consistent profitability and a history of volatile earnings surprises make it a high-risk speculative play.
Compare Another Pair
Related Comparisons
PLSM vs TXMD: Head-to-Head Comparison
This page compares Pulsenmore Ltd. (PLSM) and TherapeuticsMD, Inc. (TXMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.